Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 214

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Engineering cytokine therapeutics

Open access
Deckers, Jeroen, Anbergen, Tom, Hokke, Ayla M., de Dreu, Anne, Schrijver, David P., de Bruin, Koen, Toner, Yohana C., Beldman, Thijs J., Spangler, Jamie B., de Greef, Tom F. A., Grisoni, Francesca, van der Meel, Roy, Joosten, Leo A. B., Merkx, Maarten, Netea, Mihai G., Mulder, Willem J. M. · 2023 · Nature Reviews Bioengineering

Abstract

Cytokines have pivotal roles in immunity, making them attractive as therapeutics for a variety of immune-related disorders. However, the widespread clinical use of cytokines has been limited by their short blood half-lives and severe side effects caused by low specificity and unfavourable biodistribution. Innovations in bioengineering have aided in advancing our knowledge of cytokine biology and yielded new technologies for cytokine engineering. In this Review, we discuss how the development of bioanalytical methods, such as sequencing and high-resolution imaging combined with genetic techniques, have facilitated a better understanding of cytokine biology. We then present an overview of therapeutics arising from cytokine re-engineering, targeting and delivery, mRNA therapeutics and cell therapy. We also highlight the application of these strategies to adjust the immunological imbalance in different immune-mediated disorders, including cancer, infection and autoimmune diseases. Finally, we look ahead to the hurdles that must be overcome before cytokine therapeutics can live up to their full potential. Cytokines are key regulators of the immune system and can be recombinantly designed as therapeutics for immune-related disorders. However, the severe toxicity of recombinant cytokines limits their clinical translation. In this Review, the authors highlight bioengineering approaches for the design of clinically applicable and safe cytokine-based therapeutics. Cytokines are crucial regulators of the immune system and have important roles in health and disease. Recombinant cytokine therapy is hampered by the short blood half-life and severe side effects of cytokines. Increased knowledge of cytokine biology converges with new bioengineering approaches to develop engineered cytokine therapeutics. Cytokine therapeutics can be applied to modulate dysregulated immune responses in disorders such as cancer or autoimmune diseases. Cytokines are crucial regulators of the immune system and have important roles in health and disease. Recombinant cytokine therapy is hampered by the short blood half-life and severe side effects of cytokines. Increased knowledge of cytokine biology converges with new bioengineering approaches to develop engineered cytokine therapeutics. Cytokine therapeutics can be applied to modulate dysregulated immune responses in disorders such as cancer or autoimmune diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s44222-023-00030-y

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 171

  1. Altan-Bonnet, G. & Mukherjee, R. Cytokine-mediated communication: a quantitative appraisal of immune complexity. Nat. Rev. Immunol. 19, 205–217 (2019). · DOI · Paper page
  2. Stanley, A. C. & Lacy, P. Pathways for cytokine secretion. Physiology 25, 218–229 (2010). · DOI · Paper page
  3. Leonardi, C. L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665–1674 (2008). · DOI · Paper page
  4. Saenz, S. A., Taylor, B. C. & Artis, D. Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol. Rev. 226, 172–190 (2008). · DOI · Paper page
  5. Eyerich, S., Eyerich, K., Cavani, A. & Schmidt-Weber, C. IL-17 and IL-22: siblings, not twins. Trends Immunol. 31, 354–361 (2010). · DOI · Paper page
  6. Gharee-Kermani, M. & Pham, S. Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr. Pharm. Des. 7, 1083–1103 (2001). · DOI · Paper page
  7. Hughes, C. E. & Nibbs, R. J. B. A guide to chemokines and their receptors. FEBS J. 285, 2944–2971 (2018). · DOI · Paper page
  8. Roan, F., Obata-Ninomiya, K. & Ziegler, S. F. Epithelial cell-derived cytokines: more than just signaling the alarm. J. Clin. Invest. 129, 1441–1451 (2019). · DOI · Paper page
  9. Smith, D. E. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin. Exp. Allergy 40, 200–208 (2010). · DOI · Paper page
  10. Ihle, J. N. Cytokine receptor signalling. Nature 377, 591–594 (1995). · DOI · Paper page
  11. O’Shea, J. J., Gadina, M. & Siegel, R. M. in Clinical Immunology 5th edn Ch. 9 (eds Rich, R. R. et al.) 127–155.e1 (2019). · DOI
  12. Arts, R. J. W. et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23, 89–100.e5 (2018). · DOI · Paper page
  13. Guo, L., Junttila, I. S. & Paul, W. E. Cytokine-induced cytokine production by conventional and innate lymphoid cells. Trends Immunol. 33, 598 (2012). · DOI
  14. Rousset, F., Garcia, E. & Banchereau, J. Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J. Exp. Med. 173, 705–710 (1991). · DOI · Paper page
  15. Tough, D. F., Borrow, P. & Sprent, J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272, 1947–1950 (1996). · DOI · Paper page
  16. Ross, M. E. & Caligiuri, M. A. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 89, 910–918 (1997). · DOI
  17. Lin, J. X. et al. The role of shared receptor motifs and common stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2, 331–339 (1995). · DOI · Paper page
  18. Berraondo, P. et al. Cytokines in clinical cancer immunotherapy. Br. J. Cancer 120, 6–15 (2019). · DOI · Paper page
  19. Ozaki, K. & Leonard, W. J. Cytokine and cytokine receptor pleiotropy and redundancy. J. Biol. Chem. 277, 29355–29358 (2002). · DOI · Paper page
  20. Yoshimoto, T. et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J. Immunol. 161, 3400–3407 (1998). · DOI · Paper page
  21. Waldmann, T. A. The shared and contrasting roles of interleukin-2 (IL-2) and IL-15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol. Res. 3, 219 (2015). · DOI · Paper page
  22. Royall, J. A. et al. Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 257, L399–L410 (1989). · DOI · Paper page
  23. Hafler, D. A. Cytokines and interventional immunology. Nat. Rev. Immunol. 7, 423–423 (2007). · doi:10.1038/nri2101
  24. Monaco, C., Nanchahal, J., Taylor, P. & Feldmann, M. Anti-TNF therapy: past, present and future. Int. Immunol. 27, 55–62 (2015). · DOI · Paper page
  25. Ly, K. et al. Anti IL-17 in psoriasis. Expert Rev. Clin. Immunol. 15, 1185–1194 (2019). · DOI
  26. van de Veerdonk, F. L. et al. A guide to immunotherapy for COVID-19. Nat. Med. 28, 39–50 (2022). · DOI · Paper page
  27. Herman, A. C., Boone, T. C. & Lu, H. S. in Formulation, Characterization, and Stability of Protein Drugs (eds Pearlman, R. & Wang, Y. J.) 303–328 (Springer, 2002). · doi:10.1007/0-306-47452-2_7
  28. Rasenack, J. et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]. Pharmacoeconomics 21, 341–349 (2003). · DOI
  29. Baldo, B. A. Side effects of cytokines approved for therapy. Drug Safety 37, 921–943 (2014). · DOI · Paper page
  30. Golomb, H. M. et al. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J. Clin. Oncol. 4, 900–905 (1986). · doi:10.1200/jco.1986.4.6.900
  31. Cohen, J. IL-12 deaths: explanation and a puzzle. Science 270, 908 (1995). · doi:10.1126/science.270.5238.908.a · Paper page
  32. Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105–2116 (1999). · DOI · Paper page
  33. Sanger, F., Nicklen, S. & Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl Acad. Sci. USA 74, 5463–5467 (1977). · DOI · Paper page
  34. Karas, M. & Hillenkamp, F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal. Chem. 60, 2299–2301 (1988). · DOI · Paper page
  35. Tanaka, K. et al. Protein and polymer analyses up to mlz 100 000 by laser ionization time-of-flight mass spectrometry. Rapid Commun. Mass. Spectrom. 2, 151–153 (1988). · DOI · Paper page
  36. Williamson, M. P., Havel, T. F. & Wüthrich, K. Solution conformation of proteinase inhibitor IIA from bull seminal plasma by 1H nuclear magnetic resonance and distance geometry. J. Mol. Biol. 182, 295–315 (1985). · DOI · Paper page
  37. Woolfson, M. M. The development of structural x-ray crystallography. Phys. Scr. 93, 032501 (2018). · DOI
  38. Matadeen, R., Hon, W. C., Heath, J. K., Jones, E. Y. & Fuller, S. The dynamics of signal triggering in a gp130-receptor complex. Structure 15, 441–448 (2007). · DOI
  39. Wang, X., Rickert, M., Garcia, K. C. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 310, 1159–1163 (2005). · DOI · Paper page
  40. Gaffen, S. L. Signaling domains of the interleukin 2 receptor. Cytokine 14, 63–77 (2001). · DOI · Paper page
  41. Johnson, K., Granzow, R., Creasey, A. & Ciardelli, T. Ligand binding analyses and functional activity of interleukin-2 receptor ectodomains. Methods 6, 199–205 (1994). · doi:10.1006/meth.1994.1022
  42. Truneh, A. et al. Temperature-sensitive differential affinity of TRAIL for its receptors: DR5 is the highest affinity receptor. J. Biol. Chem. 275, 23319–23325 (2000). · DOI · Paper page
  43. Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature 484, 529–533 (2012). The researchers employed directed evolution to engineer an IL-2 ‘superkine’ (MDNA11) with improved antitumour properties and reduced toxicity that is now undergoing a phase I/II clinical trial. · DOI · Paper page
  44. Lumsden, A. & Wilkinson, D. The promise of gene ablation. Nature 347, 335–336 (1990). · DOI
  45. Kluger, M. J., Kozak, W., Leon, L. R. & Conn, C. A. The use of knockout mice to understand the role of cytokines in fever. Clin. Exp. Pharmacol. Physiol. 25, 141–144 (1998). · DOI
  46. Ingman, W. V. & Jones, R. L. Cytokine knockouts in reproduction: the use of gene ablation to dissect roles of cytokines in reproductive biology. Hum. Reprod. Update 14, 179–192 (2008). · DOI
  47. McCaughtry, T. M. et al. Conditional deletion of cytokine receptor chains reveals that IL-7 and IL-15 specify CD8 cytotoxic lineage fate in the thymus. J. Exp. Med. 209, 2263–2276 (2012). · DOI
  48. Archambault, L. S., Trzilova, D., Gonia, S., Gale, C. & Wheeler, R. T. Intravital imaging reveals divergent cytokine and cellular immune responses to Candida albicans and Candida parapsilosis. mBio 10, e00266-19 (2019). · DOI
  49. van de Donk, P. P. et al. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. Eur. J. Nucl. Med. Mol. Imaging 48, 4369–4376 (2021). · DOI
  50. Zhang, T., Warden, A. R., Li, Y. & Ding, X. Progress and applications of mass cytometry in sketching immune landscapes. Clin. Transl Med. 10, e206 (2020). · DOI
  51. Iyer, A., Hamers, A. A. J. & Pillai, A. B. CyTOF® for the masses. Front. Immunol. 13, 815828 (2022). · DOI
  52. Jiang, P. et al. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels. Nat. Methods 18, 1181–1191 (2021). · DOI · Paper page
  53. Hahn, N. et al. The orphan cytokine receptor CRLF3 emerged with the origin of the nervous system and is a neuroprotective erythropoietin receptor in locusts. Front. Mol. Neurosci. 12, 251 (2019). · DOI
  54. Carter, P. Site-directed mutagenesis. Biochemistry 237, 1–7 (1986). · DOI · Paper page
  55. Packer, M. S. & Liu, D. R. Methods for the directed evolution of proteins. Nat. Rev. Genet. 16, 379–394 (2015). · DOI · Paper page
  56. Krieg, C., Létourneau, S., Pantaleo, G. & Boyman, O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl Acad. Sci. USA 107, 11906–11911 (2010). · DOI · Paper page
  57. Junttila, I. S. et al. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat. Chem. Biol. 8, 990–998 (2012). · DOI
  58. Mueller, T. D., Zhang, J.-L., Sebald, W. & Duschl, A. Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim. Biophys. Acta Mol. Cell Res. 1592, 237–250 (2002). · DOI · Paper page
  59. Gorby, C. et al. Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses. Sci. Signal. 13, eabc0653 (2020). · DOI
  60. Zhou, T. et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583, 609–614 (2020). · DOI · Paper page
  61. Saxton, R. A. et al. The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design. Immunity 54, 660–672.e9 (2021). · DOI
  62. Saxton, R. A. et al. Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10. Science 371, eabc8433 (2021). · DOI · Paper page
  63. Mendoza, J. L. et al. Structure of the IFNγ receptor complex guides design of biased agonists. Nature 567, 56–60 (2019). · DOI
  64. Carmenate, T. et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J. Immunol. 190, 6230–6238 (2013). · DOI
  65. Chen, X. et al. A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2. Cell Death Dis. 9, 989 (2018). · doi:10.1038/s41419-018-1047-2
  66. Shanafelt, A. B. et al. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat. Biotechnol. 18, 1197–1202 (2000). · DOI
  67. Peterson, L. B. et al. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. J. Autoimmun. 95, 1–14 (2018). · DOI
  68. Ghelani, A. et al. Defining the threshold IL-2 signal required for induction of selective Treg cell responses using engineered IL-2 muteins. Front. Immunol. 11, 1106 (2020). · DOI
  69. Visweswaraiah, J. et al. Generation of PT101, a highly selective IL-2 mutein for treatment of autoimmune diseases. Ann. Rheum. Dis. 80, 13–13 (2021). · doi:10.1136/annrheumdis-2021-eular.2097
  70. Khoryati, L. et al. An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice. Sci. Immunol. 5, eaba5264 (2020). · DOI
  71. Molineux, G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 23, 3S–8S (2003). · DOI
  72. Meyers, F. J., Paradise, C., Scudder, S. A., Goodman, G. & Konrad, M. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2. Clin. Pharmacol. Ther. 49, 307–313 (1991). · DOI
  73. Mattijssen, V. et al. Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma. Ann. Oncol. 5, 957–960 (1994). · doi:10.1093/oxfordjournals.annonc.a058739
  74. Emmerich, J. et al. IL-10 directly activates and expands tumor-resident CD8+ T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 72, 3570–3581 (2012). · DOI · Paper page
  75. Naing, A. et al. PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients. Cancer Cell 34, 775–791.e3 (2018). · DOI · Paper page
  76. Ptacin, J. L. et al. An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism. Nat. Commun. 12, 4785 (2021). The researchers developed a rationally PEGylated form of IL-2 (THOR-707) that selectively expands and activates effector T cells and NK cells and is undergoing a phase I/II clinical trial. · DOI
  77. Charych, D. H. et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin. Cancer Res. 22, 680–690 (2016). · DOI · Paper page
  78. Dixit, N. et al. NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J. Transl Autoimmun. 4, 100103 (2021). · DOI
  79. Miyazaki, T. et al. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy. J. Immunother. Cancer 9, e002024 (2021). · DOI
  80. Sellaturay, P., Nasser, S., Islam, S., Gurugama, P. & Ewan, P. W. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin. Exp. Allergy 51, 861–863 (2021). · DOI · Paper page
  81. Pan, X. & Kortemme, T. Recent advances in de novo protein design: principles, methods, and applications. J. Biol. Chem. 296, 100558 (2021). · DOI · Paper page
  82. Goldenzweig, A. et al. Automated structure- and sequence-based design of proteins for high bacterial expression and stability. Mol. Cell 63, 337–346 (2016). · DOI · Paper page
  83. Khersonsky, O. et al. Automated design of efficient and functionally diverse enzyme repertoires. Mol. Cell 72, 178–186.e5 (2018). · DOI · Paper page
  84. Wang, J., Cao, H., Zhang, J. Z. H. & Qi, Y. Computational protein design with deep learning neural networks. Sci. Rep. 8, 6349 (2018). · DOI · Paper page
  85. Lin, E., Lin, C. H. & Lane, H. Y. De novo peptide and protein design using generative adversarial networks: an update. J. Chem. Inf. Model. 62, 761–774 (2022). · DOI
  86. Leman, J. K. et al. Macromolecular modeling and design in Rosetta: recent methods and frameworks. Nat. Methods 17, 665–680 (2020). · DOI · Paper page
  87. Yen, M. et al. Facile discovery of surrogate cytokine agonists. Cell 185, 1414–1430.e19 (2022). · DOI
  88. Moraga, I. et al. Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers. eLife 6, 22882 (2017). · DOI
  89. Emmerich, J. et al. Abstract 1744: STK-012, an α/β selective IL-2 mutein for the activation of the antigen-activated T cells in solid tumor. Cancer Res. 81, 1744–1744 (2021). · doi:10.1158/1538-7445.am2021-1744
  90. Ren, J. et al. Interleukin-2 superkines by computational design. Proc. Natl Acad. Sci. USA 119, e2117401119 (2022). · DOI
  91. Harvill, E. T. & Morrison, S. L. An IgG3–IL2 fusion protein activates complement, binds FcγRI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1, 95–105 (1995). · doi:10.1016/1380-2933(95)00009-7
  92. Peng, L. S., Penichet, M. L. & Morrison, S. L. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol. 163, 250–258 (1999). · doi:10.4049/jimmunol.163.1.250
  93. Halin, C. et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 20, 264–269 (2002). · DOI · Paper page
  94. Castellani, P. et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59, 612–618 (1994). · DOI · Paper page
  95. Fallon, J. et al. The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget 5, 1869–1884 (2014). The researchers fused IL-12 to a histone-binding antibody to engineer an immunocytokine target’s exposed DNA found at the site of the tumour. · DOI · Paper page
  96. Zhang, L. et al. Imaging the alternatively spliced D domain of tenascin C in preclinical models of inflammatory bowel disease. Mol. Imaging Biol. https://doi.org/10.1007/s11307-022-01758-6 (2022). · DOI
  97. Tzeng, A., Kwan, B. H., Opel, C. F., Navaratna, T. & Wittrup, K. D. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc. Natl Acad. Sci. USA 112, 3320–3325 (2015). · DOI
  98. Spangler, J. B. et al. Engineering a single-agent cytokine/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy. J. Immunol. 201, 2094–2106 (2018). · DOI
  99. Huyghe, L. et al. Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies. EMBO Mol. Med. 12, e11223 (2020). · DOI
  100. Cauwels, A. & Tavernier, J. Tolerizing strategies for the treatment of autoimmune diseases: from ex vivo to in vivo strategies. Front. Immunol. 11, 674 (2020). · DOI
  101. Hank, J. A. et al. Immunogenicity of the Hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin. Cancer Res. 15, 5923–5930 (2009). · doi:10.1158/1078-0432.ccr-08-2963
  102. Momin, N. et al. Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci. Transl Med. 11, 2614 (2019). The researchers fused pro-inflammatory cytokines to a collagen-binding protein to engineer cytokine fusion proteins with increased tumour retention. · DOI · Paper page
  103. Agarwal, Y. et al. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nat. Biomed. Eng. 6, 129–143 (2022). · DOI
  104. Mansurov, A. et al. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat. Biomed. Eng. 4, 531–543 (2020). · DOI · Paper page
  105. Rautio, J., Meanwell, N. A., Di, L. & Hageman, M. J. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug Discov. 17, 559–587 (2018). · DOI · Paper page
  106. López-Otín, C. & Matrisian, L. M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800–808 (2007). · DOI · Paper page
  107. Hsu, E. J. et al. A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nat. Commun. 12, 2768 (2021). · DOI
  108. O’Neil, J. et al. Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates. J. Clin. Oncol. 39, 2563–2563 (2021). The researchers developed an IL-2 prodrug that is inactive until the inactivation unit is cleaved by tumour-associated proteases. · doi:10.1200/jco.2021.39.15_suppl.2563
  109. Mansurov, A. et al. Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker. Nat. Biomed. Eng. 6, 819–829 (2022). · DOI
  110. Nirschl, C. et al. WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models. J. Immunother. Cancer 9, A747–A747 (2021). · doi:10.1136/jitc-2021-sitc2021.718
  111. Steiner, P. et al. Conditionally activated IL-12 or IFNα indukineTM molecules inhibit syngeneic lymphoma tumor growth in mice, induce anti-tumor immune responses and are tolerated in non-human primates. Blood 138, 2258–2258 (2021). · doi:10.1182/blood-2021-152758
  112. Rosen, D. B. et al. TransConTM IL-2 β/γ: a novel long-acting prodrug of receptor-biased IL-2 designed for improved pharmocokinetics and optimal activation of T cells for the treatment of cancer [abstract 4507]. Immunology 80, 4507–4507 (2020).
  113. Zhang, Y., Li, N., Suh, H. & Irvine, D. J. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. Nat. Commun. 9, 6 (2018). The researchers anchored IL-2 and anti-CD137 on the surface of liposomes to improve tumour accumulation and decrease systemic toxicity. · DOI · Paper page
  114. Kamaly, N. et al. Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis. ACS Nano 10, 5280–5292 (2016). · DOI · Paper page
  115. Kawasaki, T. & Kawai, T. Toll-like receptor signaling pathways. Front. Immunol. 5, 461 (2014). · DOI · Paper page
  116. Alameh, M.-G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892.e7 (2021). · DOI · Paper page
  117. Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer–BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543–555 (2022). · DOI · Paper page
  118. Liu, J. Q. et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J. Control. Release 345, 306–313 (2022). · DOI · Paper page
  119. Hotz, C. et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci. Transl Med. 13, eabc7804 (2021). · DOI · Paper page
  120. Melero, I., Castanon, E., Alvarez, M., Champiat, S. & Marabelle, A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558–576 (2021). · DOI · Paper page
  121. Lai, I. et al. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. J. Immunother. Cancer 6, 125 (2018). In this study, a lipid nanoparticle encapsulating mRNA encoding IL-12 was intravenously administered to treat hepatocellular carcinoma. · DOI
  122. van Leent, M. M. T. et al. Regulating trained immunity with nanomedicine. Nat. Rev. Mater. 7, 465–481 (2022). · DOI
  123. Morotti, M. et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br. J. Cancer 124, 1759–1776 (2021). · DOI · Paper page
  124. Gajewski, T. F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268–276 (2013). · DOI · Paper page
  125. Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S. & Brentjens, R. J. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 4, e994446 (2015). · DOI · Paper page
  126. Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D. & Brentjens, R. J. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci. Rep. 7, 10541 (2017). · DOI · Paper page
  127. Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278–2288 (2015). · DOI · Paper page
  128. Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372–385 (2019).
  129. Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99, 16168–16173 (2002). · DOI · Paper page
  130. Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346–351 (2018). · DOI · Paper page
  131. Andersen, R. et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin. Cancer Res. 22, 3734–3745 (2016). · DOI · Paper page
  132. Lee, J. M. et al. Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model. Cancer Gene Ther. 17, 742–750 (2010). · DOI
  133. Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 359, 1037–1042 (2018). The researchers developed an orthogonal IL-2 cytokine–receptor complex that selectively potentiates engineered T cells for engineered cell therapies. · DOI · Paper page
  134. Zhang, Q. et al. A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci. Transl Med. 13, 6986 (2021). · DOI
  135. Hirai, T. et al. Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance. J. Clin. Invest. 131, e139991 (2021). · DOI
  136. Taylor, P. A. et al. L-selectinhi but not the L-selectinlo CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 104, 3804–3812 (2004). · DOI · Paper page
  137. Mo, F. et al. An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature 597, 544–548 (2021). · DOI · Paper page
  138. Pohl-Guimarães, F. et al. RNA-modified T cells mediate effective delivery of immunomodulatory cytokines to brain tumors. Mol. Ther. 27, 837–849 (2019). · DOI
  139. Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic Notch receptors. Cell 167, 419–432.e16 (2016). · DOI · Paper page
  140. Yao, W. et al. Intratumoral injection of dendritic cells overexpressing interleukin-12 inhibits melanoma growth. Oncol. Rep. 42, 370–376 (2019).
  141. Minkis, K. et al. Type 2 bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res. 68, 9441–9450 (2008). · DOI
  142. Tatsumi, T. et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity 1. Cancer Res. 63, 6378–6386 (2003).
  143. Bontkes, H. J. et al. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther. 14, 366–375 (2007). · DOI
  144. Naka, T. et al. Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA. Cancer Sci. 99, 407–413 (2008). · DOI
  145. van den Bergh, J. et al. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget 6, 44123–44133 (2015). · DOI
  146. Kang, M. et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv. Mater. 33, 2103258 (2021). · DOI · Paper page
  147. Wang, S. et al. CAR-macrophage: an extensive immune enhancer to fight cancer. eBioMedicine 76, 103873 (2022). · DOI
  148. Kaczanowska, S. et al. Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. Cell 184, 2033–2052.e21 (2021). · DOI · Paper page
  149. Nash, A. M. et al. Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors. Sci. Adv. 8, 1032 (2022). · DOI
  150. Mosallaei, M. et al. Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication. Cancer Gene Ther. 27, 854–868 (2020). · DOI
  151. Razeghian, E. et al. Mesenchymal stem/stromal cells as a vehicle for cytokine delivery: an emerging approach for tumor immunotherapy. Front. Med. 8, 1405 (2021). · DOI
  152. Adams, G. P. & Weiner, L. M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147–1157 (2005). · DOI · Paper page
  153. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996). · DOI · Paper page
  154. Perrillo, R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 49, S103–S111 (2009). · DOI · Paper page
  155. Panitch, H. S. Interferons in multiple sclerosis. Drugs 44, 946–962 (1992). · DOI
  156. Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688–696 (1995). · DOI · Paper page
  157. Bennett, C. L., Djulbegovic, B., Norris, L. B. & Armitage, J. O. Colony-stimulating factors for febrile neutropenia during cancer therapy. N. Engl. J. Med. 368, 1131–1139 (2013). · DOI · Paper page
  158. Zhang, P., Sun, F., Liu, S. & Jiang, S. Anti-PEG antibodies in the clinic: current issues and beyond PEGylation. J. Control. Release 244, 184–193 (2016). · DOI · Paper page
  159. Mitra, S. et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity 42, 826–838 (2015). · DOI · Paper page
  160. Mould, D. R. & Green, B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 24, 23–39 (2010). · DOI · Paper page
  161. Ghoreschi, K. et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9, 40–46 (2002). · DOI · Paper page
  162. Tulpule, A. et al. Interleukin-4 in the treatment of AIDS-related Kaposi’s sarcoma. Ann. Oncol. 8, 79–83 (1997). · DOI
  163. Sportès, C. et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 205, 1701–1714 (2008). · DOI · Paper page
  164. Buruiana, F. E., Solà, I. & Alonso-Coello, P. Recombinant human interleukin 10 for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2012, CD005109 (2010).
  165. Colombel, J. F. et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn’s disease. Gut 49, 42–46 (2001). · DOI · Paper page
  166. Chernoff, A. E. et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J. Immunol. 154, 5492–5499 (1995). · DOI · Paper page
  167. Conlon, K. C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74–82 (2015). · DOI · Paper page
  168. Petrella, T. M. et al. Final efficacy results of NCIC CTG IND.202: a randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM). J. Clin. Oncol. 31, 9032–9032 (2013). · doi:10.1200/jco.2013.31.15_suppl.9032
  169. Pina, A. S., Lowe, C. R. & Roque, A. C. A. Challenges and opportunities in the purification of recombinant tagged proteins. Biotechnol. Adv. 32, 366–381 (2014). · DOI · Paper page
  170. Malyala, P. & Singh, M. Endotoxin limits in formulations for preclinical research. J. Pharm. Sci. 97, 2041–2044 (2008). · DOI · Paper page
  171. Freitag, R. in Animal Cell Biotechnology Vol. 1104 (ed. Pörtner, R.) 419–458 (Humana, 2014). · DOI

Cited by

See all 214

Metadata

Authors
Deckers, J., Anbergen, T., Hokke, A. M., de Dreu, A., Schrijver, D. P., de Bruin, K., Toner, Y. C., Beldman, T. J., Spangler, J. B., de Greef, T. F. A., Grisoni, F., van der Meel, R., Joosten, L. A. B., Merkx, M., Netea, M. G., & Mulder, W. J. M.
Venue
Nature Reviews Bioengineering
Published
2023-02-16
Volume
1
Issue
4
Pages
286-303
ISSN
2731-6092 (ISSN-L)
OpenAlex
W4321112890
Cited by
214
References
46
FWCI
10.29
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Engineering cytokine therapeutics. https://app.cochat.ai/papers/10.1038/s44222-023-00030-y
The paper
Deckers, J., Anbergen, T., Hokke, A. M., de Dreu, A., Schrijver, D. P., de Bruin, K., Toner, Y. C., Beldman, T. J., Spangler, J. B., de Greef, T. F. A., Grisoni, F., van der Meel, R., Joosten, L. A. B., Merkx, M., Netea, M. G., & Mulder, W. J. M. (2023). Engineering cytokine therapeutics. Nature Reviews Bioengineering. https://doi.org/10.1038/s44222-023-00030-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.